Organization

The Purdue Frederick Company

Drug company that pleaded guilty in 2007 to misbranding OxyContin.

5 links, 5 backed by primary records

Legal records

Misbranding of OxyContin

2007 Convicted by U.S. District Court, Western District of Virginia: a felony count of misbranding a drug with intent to defraud and mislead 1

Connections 5

Howard Udell Executive vice president and chief legal officer Primary record 2
Michael Friedman President Primary record 2
Paul Goldenheim Executive vice president of worldwide medical affairs (former, at the 2007 plea) Primary record 2

U.S. District Court, Western District of Virginia 2007 a felony count of misbranding a drug with intent to defraud and mislead Primary record 1

Purdue Frederick guilty pleas (2007) pleaded guilty to felony misbranding OxyContin Primary record 2

Timeline 1 date

Proof 2 sources

Violations Prove Costly to Maker of OxyContin, U.S. Food and Drug Administration, 21 May 2007. Primary record
Purdue pled guilty to a felony count of misbranding a drug with intent to defraud and mislead.
In a case prosecuted by the U.S. Attorney's Office for the Western District of Virginia
trained its sales force to represent to health care providers that OxyContin didn't cause euphoria and was less addictive than immediate-release opiates
As part of the plea, Purdue will pay a $600 million settlement.
The Purdue Frederick Company, Inc. and Top Executives Plead Guilty to Misbranding OxyContin; Will Pay Over $600 Million, U.S. Attorney’s Office, Western District of Virginia, 10 May 2007. Primary record Archived copy
President and Chief Operating Officer Michael Friedman, Executive Vice President and Chief Legal Officer Howard Udell
former Executive Vice President of Worldwide Medical Affairs Paul D. Goldenheim
The Purdue Frederick Company, Inc., pleaded guilty to felony misbranding OxyContin with the intent to defraud and mislead.

Page history 1 change